Fibroblast therapies
Merck & Co. and Mestag Therapeutics Collaborate on $1.9 Billion Fibroblast Therapy Deal for Inflammatory Diseases
Merck & Co., Mestag Therapeutics, Fibroblast therapies, Inflammatory diseases, $1.9 billion deal, RAFT platform, Drug target identification